On July 22, China became the first country to approve Orzeyful, a new medication for narcolepsy type 1, for patients aged 16 and older. The National Medical Products Administration’s decision made China the first reported market to authorize the drug. The approval was an early regulatory key stage: the United States and Japan also approved Orzeyful in August 2026. The disorder causes excessive daytime sleepiness and sudden loss of muscle tone, known as cataplexy.
Orzeyful, also known as oveporexton, is an oral drug that selectively activates the orexin receptor 2 (OX2R). Existing therapies mainly manage individual symptoms. Orzeyful is designed to stimulate signaling through a receptor normally activated by orexin, a neuropeptide that helps stabilize the sleep-wake cycle. In narcolepsy type 1, orexin deficiency is linked to the disease’s hallmark symptoms. Takeda describes the drug as a targeted treatment for this underlying signaling deficit, not a cure.
How Orzeyful Works
Narcolepsy type 1 is associated with the loss of orexin-producing neurons, resulting in persistent drowsiness and cataplexy, as well as fragmented nighttime sleep. Patients may also experience sleep paralysis, hallucinations and attention difficulties. Orzeyful does not replace lost neurons. Instead, it selectively stimulates OX2R to help restore orexin signaling and promote wakefulness. The drug also targets REM-sleep-related symptoms, including cataplexy. China’s approval covers patients aged 16 and older with narcolepsy type 1, excluding younger patients and people with other hypersomnia disorders.
Clinical Trials and Results
The approval is based on two 12-week, randomized, placebo-controlled Phase 3 studies, FirstLight and RadiantLight, conducted in 19 countries and involving 273 participants. FirstLight, or TAK-861-3001, enrolled 168 patients and compared twice-daily 1-mg and 2-mg regimens with placebo. RadiantLight, or TAK-861-3002, enrolled 105 patients and compared twice-daily 2 mg with placebo. Both studies met their primary and secondary endpoints. They assessed wakefulness and daytime sleepiness, alongside cataplexy, disease severity and quality of life. Takeda reported statistically impressive improvements across the studies, with p-values below 0.001.
Trial summaries report that wakefulness on the Maintenance of Wakefulness Test increased by approximately 14.3 to 19.8 minutes with oveporexton, compared with placebo changes of about minus 0.4 to minus 0.8 minutes. Epworth Sleepiness Scale scores fell by 9.7 to 11.8 points in treatment groups, compared with 1.5 to 1.7 points with placebo. Median weekly cataplexy frequency declined by 79% to 88.8% among treated participants, versus 27.7% to 39.1% with placebo. The manufacturer also reported that nearly 85% of treated participants reached levels of sleepiness similar to those of healthy individuals. More than 95% of trial completers entered a long-term extension study.
The median reduction in weekly cataplexy episodes exceeded 80%, with patients gaining four to five cataplexy-free days per week, compared with none at baseline. No serious treatment-related adverse events were reported. The most common side effects were insomnia, urinary urgency and increased urination. The 12-week findings show improvement across several symptoms, but do not establish that treatment reverses the loss of orexin-producing neurons or changes the disease over the long term.
Scope and Limitations
Official estimates suggest that around 700,000 people in China live with some form of narcolepsy, but only 75-80% have type 1, translating to roughly 525,000-560,000 potential candidates. The age restriction means not all patients are immediately eligible. Narcolepsy often begins between ages 10 and 20, and diagnosis can be delayed for years, affecting education and employment, as well as driving and social life. The condition is also linked to higher risks of accidents, anxiety and depression. In Spain, for example, eligibility for permanent disability benefits depends on functional limitations rather than diagnosis alone. The new approval does not guarantee an immediate return to normal work activity for all patients.
International Status and Next Steps
China’s lead refers to the timing of its initial authorization, not the drug’s current regulatory standing. The U.S. Food and Drug Administration and Japan’s Ministry of Health, Labour and Welfare approved Orzeyful in August 2026. Japan’s reported authorization covers adults with narcolepsy type 1. By October, industry coverage described the drug as available in China and Japan. The U.S. launch was expected to follow completion of Drug Enforcement Administration procedures, with commercial availability projected for November 2026. The clinical trials compared Orzeyful with placebo, not directly with all existing treatments.
The number of patients who will start treatment immediately in China remains unclear. Takeda plans to launch the drug in the country in the second half of 2026, but details on pricing, reimbursement and exact availability have not been disclosed. Further access will depend on regulatory reviews and launch arrangements in each jurisdiction. Approval in one market does not establish authorization elsewhere.
